ANB033
ANB033 is a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2
IND filing to support clinical development of ANB033 anticipated in first half of 2024
Anti-CD122 antagonist reduces pathogenic TRM and NK Cells
CD122 is a shared beta subunit of the receptors for IL-15 and IL-2
CD122 antagonist mAb will potently inhibit IL-2 and IL-15 biology
CD122 antagonist mAb will potently inhibit IL-2 and IL-15 biology
Both IL-15 and IL-2 mediate:
- Proliferation and survival of NK cells and subsets of T cells
- Inflammatory cytokine secretion (IFNγ) during T cell activation
IL-15 mediates survival of TRM cells
High affinity antagonist antibody reduces pathogenic cells by preferentially inhibiting the lower affinity dimeric receptor complex
- Spares Tregs which express higher affinity IL-2 trimeric receptor complex
Targeted reduction of TRM cells may potentially drive durable response
To access scientific publications on this topic, please click here.